Nanobiotix

Equities

NANO

FR0011341205

Biotechnology & Medical Research

Real-time Euronext Paris Other stock markets 09:51:39 05/07/2024 BST			5-day change	1st Jan Change
4.928 ^EUR	+1.15%		+10.74%	-25.78%

07-02	Nanobiotix: The Goldman Sachs Group crosses the 5% threshold	CF
06-25	ADRs End Higher; Nanobiotix S.A. Climbs 12%	DJ

Nanobiotix SA Reports Revenue Results for the Fourth Quarter and Full Year of 2012

January 25, 2013 at 05:19 pm

Nanobiotix SA reported revenue results for the fourth quarter and full year of 2012. For the quarter, the company reported revenues came to EUR 46,409.

For the year, the company reported revenue of EUR 74,153.

Latest news about Nanobiotix

Nanobiotix: The Goldman Sachs Group crosses the 5% threshold	07-02	CF
ADRs End Higher; Nanobiotix S.A. Climbs 12%	06-25	DJ
Stifel Initiates Nanobiotix with Buy Rating	06-25	MT
Nanobiotix: well oriented on broker's comments	06-25	CF
NANOBIOTIX : Stifel initiates buy coverage	06-25	CF
Transcript : Nanobiotix S.A. - Special Call	06-18
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated with RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy	06-03	CI
Transcript : Nanobiotix S.A. - Special Call	06-02
Nanobiotix S.A. Announces Presentation of New Data from Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology	05-28	CI
Transcript : Nanobiotix S.A., Q1 2024 Earnings Call, May 22, 2024	05-22
Nanobiotix: strategy update, share price declines	05-22	CF
Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship	05-21	MT
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth	05-21	CI
Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment	05-14	MT
Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer	05-14	CI
Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024	04-25
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Nanobiotix S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	04-24	CI
Nanobiotix completes escalation portion of 2020-0123 study	04-03	CF
Nanobiotix Completes Dose Escalation Segment of Phase 1 Study Targeting Non-Small Cell Lung Cancer	04-02	MT
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommends Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation	04-02	CI
Nanobiotix Gets $20 Million Milestone Payment in Phase 3 Trial for Potential Head, Neck Cancer Drug	01-30	MT
Nanobiotix: targets achieved for NANORAY-312	01-30	CF
Nanobiotix Gets $20 Million Milestone Payment from Janssen	01-30	MT
Nanobiotix: transfer of NBTXR3 rights in Asia	12-27	CF

Chart Nanobiotix

Duration

Period

More charts

Company Profile

Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: NBTXR3, which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

Sector

Biotechnology & Medical Research

Calendar

03/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Nanobiotix

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.872 EUR

Average target price

11.68 EUR

Spread / Average Target

+139.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NANOBIOTIX	-25.78%	248M
MODERNA, INC.	+16.59%	44.44B
LONZA GROUP AG	+42.55%	40.03B
IQVIA HOLDINGS INC.	-10.62%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.46B
CELLTRION, INC.	-9.23%	27.29B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.53%	13.8B
MEDPACE HOLDINGS, INC.	+31.49%	12.46B
BIO-TECHNE CORPORATION	-7.40%	11.26B

Other Biotechnology & Medical Research